Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies - Top-Institutions - MDSpire

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

By
Zhongfei Tao
Zuzana Chyra
Jana Kotulová
Piotr Celichowski
Jana Mihályová
Sandra Charvátová
Roman Hájek
December 3, 2024
0 min

Blood Cancer Journal

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

#1

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Hematology
- Oncology
- Immunotherapy
- Cellular Therapy
#2

University of Pennsylvania (Perelman School of Medicine)

Philadelphia, PA
Key Differentiators
- Hematology
- Immunotherapy
- Cellular Therapy
- Oncology
#3

Fred Hutchinson Cancer Center

Seattle, WA
Key Differentiators
- Hematology
- Immunotherapy
- Cellular Therapy
- Oncology
#4

MD Anderson Cancer Center

Houston, TX
Key Differentiators
- Hematology
- Oncology
- Immunotherapy
- Cellular Therapy
#5

National Cancer Institute (NCI)

Bethesda, MD
Key Differentiators
- Cancer Immunotherapy
- Hematology
- Cellular Therapy

Original Source(s)

Blood Cancer Journal

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

by Zhongfei Tao, Zuzana Chyra, Jana Kotulová, Piotr Celichowski, Jana Mihályová, Sandra Charvátová, Roman Hájek
December 3, 2024

Related Content

Frontiers In Oncology

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

by Xinlong Xu, Chang Dong, Jiashuo Guo, Xiaolin Chang, Yu Zhang, Shuting Gou, Liying Xue, Jie Li
April 29, 2026

Bone Marrow Transplantation

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Frontiers In Immunology

HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells